Xechem International, Inc. v. The University of Texas M.D. Anderson Cancer Center and Board of Regents of the University of Texas System

382 F.3d 1324, 72 U.S.P.Q. 2d (BNA) 1253, 2004 U.S. App. LEXIS 18512, 2004 WL 1932653
Court of Appeals for the Federal Circuit·Decided August 31, 2004·No. 03-1406·Published·Cited by 23 cases

Opinion

PAULINE NEWMAN, Circuit Judge.

Xechem International, Inc., a biophar-maceutical company, brought suit against the University of Texas M.D. Anderson Cancer Center and the Board of Regents of the University of Texas System (collectively “the University”) in the United States District Court, raising several federal and state counts arising from a collaborative project between Xechem and the University. In response to the complaint the University asserted its Eleventh Amendment and state immunity from suit, and the United States District Court for the Southern District of Texas granted the University’s motion to dismiss on the pleadings, Fed.R.Civ.P. 12(b)(6). 1 The only issue on appeal is whether the University is subject to suit in federal court to obtain correction of the inventorship of United States Patents No. 5,877,205 and 6,107,333, the patents flowing from the project.

We affirm the dismissal, for Supreme Court precedent controls the arguments raised by Xechem with respect to waiver or abrogation of the University’s Eleventh Amendment immunity.

Standards of Review

The University’s motion to dismiss was brought under Fed.R.Civ.P. 12(b)(6) (dismissal for failure to state a claim upon which relief can-be granted). When dismissal is on the pleadings, the plaintiffs well-pleaded factual allegations are accepted as true and all reasonable factual inferences are drawn in its favor. See Albright v. Oliver, 510 U.S. 266, 268, 114 S.Ct. 807, 127 L.Ed.2d 114 (1994) (on motion to dismiss on the pleadings, disputed material facts are viewed in the light most favorable to the complainant).

Dismissal under Rule 12(b)(6) receives plenary appellate review. Boyle v. United States, 200 F.3d 1369, 1371 (Fed.Cir.2000); Young v. AGB Corp., 152 F.3d 1377, 1379 (Fed.Cir.1998). Matters of con *1327 stitutional law and interpretation also receive plenary review. Arbon Steel & Serv. Co. v. United States, 315 F.3d 1332, 1334 (Fed.Cir.2003); Florida Sugar Mktg. & Terminal Assoc., Inc. v. United States, 220 F.3d 1331, 1333 (Fed.Cir.2000).

BACKGROUND

The basic facts are generally undisputed: Xechem and the University in 1995 entered into a Sponsored Laboratory Study Agreement, with financial and technical support by Xechem, for the purpose of developing a pharmaceutical formulation that would enhance the solubility and thereby the effectiveness of the cancer drug paclitaxel. The persons principally involved in the project were Dr. Ramesh C. Pandey, president and CEO of Xechem; Dr. Luben K. Yankov, a scientist employed by Xechem; and Dr. Borje S. Andersson and Dr. Elias Anaissie, scientists employed by the University.

The complaint states that a successful formulation was developed, and that Xe-chem prepared a patent application naming Dr. Pandey of Xechem and Dr. Andersson of the University as joint inventors, and in early 1996 sent the draft application to the University. The University objected to the designation of inventorship, and on June 28, 1996 the University filed a patent application in the United States Patent and Trademark Office, naming Dr. Andersson as sole inventor. On November 13, 1996 Dr. Pandey wrote to the University as follows:

Further to our conversation of today, as you have requested I am now forwarding you this letter in which I recognize Dr. Borge S. Andersson, as the sole inventor of the above referenced patent application.
I look forward to receiving Dr. An-dersson’s comments of the Draft Patent Application and to wrap-up the licensing negotiations concerning the subject matter of the application.

On August 18, 1997 Xechem and the University entered into a Patent and Technology License Agreement whereby Xe-chem received the exclusive worldwide license to manufacture and market these paclitaxel formulations, and Xechem agreed to pay certain continuing sums and a royalty. Xechem also agreed to pay the costs of obtaining the patents in the United States and foreign countries. The University’s patent application issued as the '205 patent on March 2, 1999, and a divisional application, also naming Dr. Anders-son as sole inventor, issued as the '333 patent on August 22, 2000. Both patents were assigned by Dr. Andersson to the University.

On February 15, 2000 Xechem was notified that the University considered the License Agreement to have terminated automatically no later then December 31, 1998, due to Xechem’s alleged insolvency, and that any use of this technology by Xechem was deemed to be patent infringement. Xechem then filed suit in federal court, presenting several counts sounding in tort and contract and also seeking correction of inventorship and a declaration of non-infringement. Xechem stated that Dr. Pandey made a mistake when he acquiesced in the naming of Dr. Andersson as sole inventor, and asked the court to determine the correct inventorship. Apparently upon the University’s claim of sovereign immunity from state as well as federal action, the state law tort and contract counts were withdrawn by Xechem. This appeal relates only to the dismissal, on Eleventh Amendment grounds, of the inventorship correction claim.

DISCUSSION

The University of Texas is deemed to be an arm of the State of Texas, see Tex.Code *1328 § 441.101(3), and Xechem does not dispute that the University is properly accorded Eleventh Amendment immunity. 2 See Regents of the Univ. of New Mexico v. Knight, 321 F.3d 1111, 1124 (Fed.Cir.2003) (recognizing the status of a state university as an arm of the state).

Free access — add to your briefcase to read the full text and ask questions with AI

Xechem International, Inc. v. The University of Texas M.D. Anderson Cancer Center and Board of Regents of the University of Texas System, 382 F.3d 1324, 72 U.S.P.Q. 2d (BNA) 1253, 2004 U.S. App. LEXIS 18512, 2004 WL 1932653 (Fed. Cir. 2004).

382 F.3d 1324 (Xechem International, Inc. v. The University of Texas M.D. Anderson Cancer Center and Board of Regents of the University of Texas System) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Benjamin Kohn v. State Bar of California
87 F.4th 1021 (Ninth Circuit, 2023)
Ali v. Carnegie Institution of Washington
684 F. App'x 985 (Federal Circuit, 2017)
Ali v. Carnegie Institution of Washington
306 F.R.D. 20 (District of Columbia, 2014)
Ali v. Carnegie Institution of Washington
967 F. Supp. 2d 1367 (D. Oregon, 2013)
Semiconductor Energy Laboratory Co. v. Nagata
706 F.3d 1365 (Federal Circuit, 2013)
Delano Farms Co. v. California Table Grape Commission
623 F. Supp. 2d 1144 (E.D. California, 2009)
Board of Regents v. Phoenix Software International, Inc.
565 F. Supp. 2d 1007 (W.D. Wisconsin, 2008)
Beane v. Beane, et al.
2008 DNH 082 (D. New Hampshire, 2008)
Pennington Seed, Inc. v. Produce Exchange No. 299
457 F.3d 1334 (Federal Circuit, 2006)
Space Exploration Technologies Corp. v. United States
68 Fed. Cl. 1 (Federal Claims, 2005)
Gant v. United States
63 Fed. Cl. 311 (Federal Claims, 2004)
Saladino v. United States
62 Fed. Cl. 782 (Federal Claims, 2004)